Header Logo

Connection

CHADI CALARGE to Adolescent

Back to Details
This is a "connection" page, showing publications CHADI CALARGE has written about Adolescent.
CHADI CALARGE
Connection Strength
1.671
Adolescent
  1. Iron Deficiency and Internalizing Symptoms Among Adolescents in the National Health and Nutrition Examination Survey. Nutrients. 2024 Oct 26; 16(21).
    View in: PubMed
    Score: 0.067
  2. Fluoxetine and Sertraline Inhibit Height Growth and Growth Hormone Signaling During Puberty. J Clin Psychopharmacol. 2024 Nov-Dec; 44(6):538-544.
    View in: PubMed
    Score: 0.067
  3. Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults. J Child Adolesc Psychopharmacol. 2023 09; 33(7):260-268.
    View in: PubMed
    Score: 0.062
  4. Utilization and Predictors of Adjuvant Metformin for Children and Adolescents on Mixed Receptor Antagonists (Second-Generation Antipsychotics). J Am Acad Child Adolesc Psychiatry. 2023 11; 62(11):1245-1255.
    View in: PubMed
    Score: 0.061
  5. Iron Deficiency in Attention-Deficit Hyperactivity Disorder, Autism Spectrum Disorder, Internalizing and Externalizing Disorders, and Movement Disorders. Child Adolesc Psychiatr Clin N Am. 2023 04; 32(2):451-467.
    View in: PubMed
    Score: 0.060
  6. Iron deficiency and internalizing symptom severity in unmedicated adolescents: a pilot study. Psychol Med. 2023 04; 53(6):2274-2284.
    View in: PubMed
    Score: 0.055
  7. Sexual Functioning in Adolescents With Major Depressive Disorder: A Prospective Study. J Clin Psychiatry. 2021 10 05; 82(6).
    View in: PubMed
    Score: 0.054
  8. Gut microbiome in adolescent depression. J Affect Disord. 2021 09 01; 292:500-507.
    View in: PubMed
    Score: 0.053
  9. Predictors of depressive symptom trajectories in a prospective follow-up of late adolescents. Psychol Med. 2020 10; 50(13):2283-2288.
    View in: PubMed
    Score: 0.047
  10. Gut permeability and depressive symptom severity in unmedicated adolescents. J Affect Disord. 2019 03 01; 246:586-594.
    View in: PubMed
    Score: 0.045
  11. CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders. J Affect Disord. 2018 10 15; 239:247-252.
    View in: PubMed
    Score: 0.044
  12. Selective Serotonin Reuptake Inhibitors Reduce Longitudinal Growth in Risperidone-Treated Boys. J Pediatr. 2018 10; 201:245-251.
    View in: PubMed
    Score: 0.043
  13. Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study. J Child Adolesc Psychopharmacol. 2018 03; 28(2):145-150.
    View in: PubMed
    Score: 0.042
  14. The Effect of Depression, Generalized Anxiety, and Selective Serotonin Reuptake Inhibitors on Change in Bone Metabolism in Adolescents and Emerging Adults. J Bone Miner Res. 2017 Dec; 32(12):2367-2374.
    View in: PubMed
    Score: 0.041
  15. CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):908-915.
    View in: PubMed
    Score: 0.041
  16. Comorbidity of Migraine, Major Depressive Disorder, and Generalized Anxiety Disorder in Adolescents and Young Adults. Int J Behav Med. 2017 08; 24(4):528-534.
    View in: PubMed
    Score: 0.041
  17. Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence. Psychiatry Res. 2017 10; 256:305-311.
    View in: PubMed
    Score: 0.040
  18. Body Composition in Adolescents During Treatment With Selective Serotonin Reuptake Inhibitors. Pediatrics. 2017 Jul; 140(1).
    View in: PubMed
    Score: 0.040
  19. Bone Mass in Boys with Autism Spectrum Disorder. J Autism Dev Disord. 2017 06; 47(6):1749-1755.
    View in: PubMed
    Score: 0.040
  20. Sexual Functioning in Adolescents With Major Depressive Disorder. J Clin Psychiatry. 2016 07; 77(7):957-62.
    View in: PubMed
    Score: 0.038
  21. Toxoplasmosis Titers and past Suicide Attempts Among Older Adolescents Initiating SSRI Treatment. Arch Suicide Res. 2016 Oct-Dec; 20(4):605-13.
    View in: PubMed
    Score: 0.037
  22. Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. J Child Adolesc Psychopharmacol. 2016 06; 26(5):471-7.
    View in: PubMed
    Score: 0.037
  23. Fat distribution and major depressive disorder in late adolescence. J Clin Psychiatry. 2016 Jan; 77(1):84-9.
    View in: PubMed
    Score: 0.037
  24. Iron homeostasis during risperidone treatment in children and adolescents. J Clin Psychiatry. 2015 Nov; 76(11):1500-5.
    View in: PubMed
    Score: 0.036
  25. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015 Oct 06; 5:e652.
    View in: PubMed
    Score: 0.036
  26. Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry. 2015 May; 76(5):607-13.
    View in: PubMed
    Score: 0.035
  27. The effect of psychostimulants on skeletal health in boys co-treated with risperidone. J Pediatr. 2015 Jun; 166(6):1449-54.e1.
    View in: PubMed
    Score: 0.035
  28. Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res. 2014 Oct; 29(10):2230-7.
    View in: PubMed
    Score: 0.034
  29. Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2014 Apr; 24(3):120-9.
    View in: PubMed
    Score: 0.032
  30. Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol. 2013 Mar; 23(2):101-9.
    View in: PubMed
    Score: 0.030
  31. Rate of weight gain and cardiometabolic abnormalities in children and adolescents. J Pediatr. 2012 Dec; 161(6):1010-5.
    View in: PubMed
    Score: 0.029
  32. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011 Dec; 72(12):1685-90.
    View in: PubMed
    Score: 0.028
  33. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9.
    View in: PubMed
    Score: 0.026
  34. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 Dec; 20(6):495-502.
    View in: PubMed
    Score: 0.026
  35. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry. 2010 Mar; 71(3):338-47.
    View in: PubMed
    Score: 0.024
  36. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009 Dec; 19(6):320-7.
    View in: PubMed
    Score: 0.024
  37. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009 May; 19(5):373-82.
    View in: PubMed
    Score: 0.023
  38. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009 Apr; 19(2):101-9.
    View in: PubMed
    Score: 0.023
  39. Fluoxetine for depression relapse prevention. J Am Acad Child Adolesc Psychiatry. 2005 Oct; 44(10):966-7; author reply 967-8.
    View in: PubMed
    Score: 0.018
  40. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
    View in: PubMed
    Score: 0.017
  41. The Effectiveness of Metformin in Managing Second Generation Antipsychotic-Induced Weight Gain in Children and Adolescents. J Clin Psychiatry. 2023 Dec 20; 85(1).
    View in: PubMed
    Score: 0.016
  42. Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
    View in: PubMed
    Score: 0.016
  43. Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
    View in: PubMed
    Score: 0.016
  44. Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
    View in: PubMed
    Score: 0.015
  45. Inflammatory Markers Profile in Older Adolescents During Treatment with Selective Serotonin Reuptake Inhibitors. J Child Adolesc Psychopharmacol. 2021 08; 31(6):439-444.
    View in: PubMed
    Score: 0.013
  46. Experiential Avoidance Predicts Persistence of Major Depressive Disorder and Generalized Anxiety Disorder in Late Adolescence. J Clin Psychiatry. 2019 10 22; 80(6).
    View in: PubMed
    Score: 0.012
  47. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013 May; 23(4):282-9.
    View in: PubMed
    Score: 0.008
  48. An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder. Ann Clin Psychiatry. 2011 Nov; 23(4):270-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.